Antithrombotic agents in coronary artery disease

Chest

Volumn 108, Issue 4 SUPPL., 1995, Pages 380S-400S

  Cairns, J A ^a   Lewis Jr , H D ^a   Meade, T W ^a   Sutton, G C ^a   Theroux, P ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; FIBRINOLYTIC AGENT; HEPARIN; MONOCLONAL ANTIBODY; PHENINDIONE; PHENPROCOUMON; SULFINPYRAZONE; TICLOPIDINE; WARFARIN;

ANGINA PECTORIS; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG EMBOLISM; META ANALYSIS; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; STROKE; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

EID: 0028839680     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.108.4_Supplement.380S     Document Type: Conference Paper

References (157)

1. Herrick JB. Clinical features of sudden obstruction of the coronary arteries JAMA 59 1912 2015 2020
2. Parkinson J Bedford DE. Cardiac infarction and coronary thrombosis Lancet 14 1928 195 239
3. Levine SA Brown CL. Coronary thrombosis: its various clinical features Medicine 8 1929 245 418
4. Sampson JJ Eliaser M. The diagnosis of impending acute coronary artery occlusion Am Heart J 13 1937 676 686
5. Feil H. Preliminary pain in coronary thrombosis Am J Med Sci 193 1937 42 48
6. Wright IS Marple CD Beck DF. Report of the committee for the evaluation of anticoagulants in the treatment of coronary thrombosis with myocardial infarction Am Heart J 36 1948 801 815
7. Craven LL. Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis Miss V Med J 75 1953 38 44
8. Gifford RH Feinstein AR. A critique of methodology in studies of anticoagulant therapy for acute myocardial infarction N Engl J Med 280 1969 351 357
9. Chapman I. The cause-effect relationship between recent coronary artery occlusion and acute myocardial infarction Am Heart J 87 1974 267 271
10. Sanz G Castanev A Bertrui A Determinants of prognosis in survivors of myocardial infarction: a prospective clinical angiographic study N Engl J Med 306 1982 1065 1071
11. Ambrose J Tannenbaum M Alexopoulos D Angiographic progression of coronary artery disease and the development of myocardial infarction J Am Coll Cardiol 12 1988 56 62
12. Little WC Constantinescu M Applegate RJ Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease Circulation 78 1988 1157 1166
13. Moise A Théroux P Taeymans Y Unstable angina and progression of coronary atherosclerosis N Engl J Med 309 1983 685 689
14. Ambrose JA Winters SL Arora RR Angiographic evolution of coronary artery morphology in unstable angina J Am Coll Cardiol 7 1986 472 478
15. Ambrose JA Winters SL Stern A Angiographic morphology and the pathogenesis of unstable angina pectoris J Am Coll Cardiol 5 1985 609 616
16. Ambrose JA Hjemdahl-Monsen CE Borrico S Angiographic demonstration of a common link between unstable angina pectoris and non-Q wave acute myocardial infarction Am J Cardiol 61 1988 244 247
17. Sherman CT Litvak F Grundfest W Coronary angioscopy in patients with unstable angina pectoris N Engl J Med 315 1986 913 919
18. DeWood MA Spores J Notske R Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction N Engl J Med 303 1980 897 902
19. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion Circulation 71 1985 699 708
20. Davies MJ Thomas AC Knapman PA Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death Circulation 73 1986 418 427
21. Davies MJ Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death N Engl J Med 310 1984 1137 1140
22. Davies MJ Bland MJ Hangartner WR Factors influencing the presence or absence of acute coronary thrombi in sudden ischemic death Eur Heart J 10 1989 203 208
23. Richardson RD Davies MJ Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques Lancet 2 1989 941 944
24. Cheng GC Loree HM Kamm RD Distribution of circumferential stress in ruptured and stable atherosclerotic lesions: a structural analysis with histopathological consideration Circulation 87 1993 1179 1187
25. Van der Wal AC Becker AE van der Loos CM Site of intimai rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology Circulation 89 1994 36 44
26. Munro JM Cotron RS. The pathogenesis of atherosclerosis: atherogenesis and inflammation Lab Invest 58 1988 249 261
27. Alexander RW. Inflammation and coronary artery disease N Engl J Med 331 1994 468 469
28. Fitzgerald DJ Roy L Catella F Platelet activation in unstable coronary disease N Engl J Med 315 1986 983 989
29. Théroux P Latour JG Léger-Gauthier C Fibrinopeptide A and platelet factor levels in unstable angina pectoris Circulation 75 1987 156 162
30. Luizzo G Biasucci LM Gallimore JR The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina N Engl J Med 331 1994 417 424
31. Folts JD Crowell EB Jr Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin Circulation 54 1976 365 370
32. 2 and thromboxane A2-prostaglandin H2 receptor blockade provide protection against epinephrine-induced cyclic flow variations in severely narrowed canine coronary arteries J Am Coll Cardiol 13 1989 755 763
33. Fuster V Badimon L Badimon JJ The pathogenesis of coronary artery disease and the acute coronary syndromes N Engl J Med 326 1992 242 50, 310–18
34. Maseri A L'Abbate A Baroldi G Coronary vasospasm as a possible cause of myocardial infarction: a conclusion derived from the study of preinfarction' angina N Engl J Med 299 1978 1271 1277
35. Chalmers TC Matta RJ Smith J Jr Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction N Engl J Med 297 1977 1091 1096
36. McMahon S Collins R Knight C Reduction in major morbidity and mortality by heparin in acute myocardial infarction [abstract] Circulation 78 suppl 2 1988 II-98
37. Assessment of short-term anticoagulant administration after cardiac infarction: report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council. BMJ 1969; 1:335-42
38. Drapkin A Merskey C. Anticoagulant therapy after acute myocardial infarction: relation of therapeutic benefit to patient's age, sex, and severity of infarction JAMA 222 1972 541 548
39. Veterans Administration Cooperative Study. Anticoagulants in acute myocardial infarction: results of a cooperative clinical trial. JAMA 1973; 225:724-29
40. Weinreich DJ Burke JF Pauletto FJ. Left ventricular mural thrombi complicating acute myocardial infarction: long-term follow-up with serial echocardiography Ann Intern Med 100 1984 789 794
41. Ezekowitz MD Kellerman DJ Smith EO Detection of active left ventricular thrombosis during acute myocardial infarction using indium-III platelet scintigraphy Chest 86 1984 35 39
42. Johannessen KA Nordrehaug JE von der lippe G. Left ventricular thrombosis and cerebrovascular accident in acute myocardial infarction Br Heart J 51 1984 553 556
43. Keating EC Gross SA Schlamowitz RA Mural thrombi in myocardial infarctions: prospective evaluation of two-dimensional echocardiography Am J Med 74 1983 989 995
44. Asinger RW Mikell FI Elsperger J Incidence of left-ventricular thrombosis after acute transmural myocardial infarction: serial evaluation by two-dimensional echocardiography N Engl J Med 305 1981 297 302
45. Spirito P Bellotti P Chiarella F Prognostic significance and natural history of left ventricular thrombi in patients with acute anterior myocardial infarction: a two-dimensional echocardiographic study Circulation 72 1985 774 780
46. Starling MR Crawford MH Sorensen SG Comparative value of invasive and noninvasive techniques for identifying left ventricular mural thrombi Am Heart J 106 1983 1143 1149
47. Gueret P Dubourg O Ferrier A Effects of full-dose heparin anticoagulation on the development of left ventricular thrombosis in acute transmural myocardial infarction J Am Coll Cardiol 8 1986 419 426
48. Visser CA Kan G Meltzer RS Embolic potential of left ventricular thrombus after myocardial infarction: a two-dimensional echocardiographic study of 119 patients J Am Coll Cardiol 5 1985 1276 1280
49. Haughland JM Asinger RW Mikell FL Embolic potential of left ventricular thrombi detected by two-dimensional echocardiography Circulation 70 1984 588 598
50. Jugdutt BI Sivarum CA Wortman CA Preoperative two-dimensional echocardiographic evaluation of left ventricular chamber wall embolism after acute myocardial infarction J Am Coll Cardiol 13 1989 554 564
51. Stratton JR Resnick AD. Increased embolic risk in patients with left ventricular thrombi Circulation 75 1987 1004 1011
52. Friedman MF Carlson K Marcus FI Clinical correlations in patients with acute myocardial infarction and left ventricular thrombus detected by two-dimensional echocardiography Am J Med 72 1982 894 898
53. Vaitkus PT Barnathau ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis J Am Coll Cardiol 22 1993 100 109
54. Steffensen KA. Coronary occlusion treated with small doses of heparin Acta Med Scand 186 1969 519 521
55. Turpie AGG Robinson JG Doyle DJ Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction N Engl J Med 320 1989 352 357
56. The SCATI (Studio sulla Calciparina nell'Angina e nella Thrombosi Ventriculare nell'Infarto) group. Randomized controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 1989; 2:182-86
57. Vecchio C Chiarella F Lupi G Left ventricular thrombus in anterior acute myocardial infarction after thrombolysis: a GISSI-2 connected study Circulation 84 1991 512 519
58. Reeder GS Lengyel M Tajik A Mural thrombus in left ventricular aneurysm: incidence, role of angiography, and relation between anticoagulation and embolization Mayo Clin Proc 56 1981 77 81
59. Simpson MT Oberman A Kouchoukos WT Prevalence of mural thrombi and systemic embolization with left ventricular aneurysm: effect of anticoagulant therapy Chest 77 1980 463 469
60. Lapeyre AC III Steele PM Kazmier FV Systemic embolization in chronic left ventricular aneurysm: incidence and the role of anticoagulation J Am Coll Cardiol 6 1985 534 538
61. Stein B Fuster V. Antithrombotic therapy in acute myocardial infarction: prevention of venous, left ventricular and coronary artery thrombosis Am J Cardiol 64 1989 33B 40B
62. Hilden T Iversen K Raaschou F Anticoagulants in acute myocardial infarction Lancet 2 1961 327 331
63. Nicolaides AN Kakkar W Renney JTG Myocardial infarction and deep-vein thrombosis BMJ 1 1971 432 434
64. Handley AJ Emerson PA Fleming PR. Heparin in the prevention of deep vein thrombosis after myocardial infarction BMJ 2 1972 436 438
65. Marks P Teather D. Subcutaneous heparin: a logical prophylaxis for deep vein thrombosis after myocardial infarction Practitioner 220 1978 425 435
66. Warlow C Beattie AG Terry G A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction Lancet 2 1973 934 940
67. Handley AJ. Low-dose heparin after myocardial infarction Lancet 2 1972 623 627
68. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: III. Reduction in venous thrombosis and preliminary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308:235-46
69. Cairns JA. Reperfusion adjunctive therapy: Heparin J Interven Cardiol 3 1990 217 223
70. Ropold HJ de Bono D Arnold AER Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase: correlation with concomitant heparin, coronary artery patency, and recurrent ischemia Circulation 85 1992 928 934
71. Yusuf S Collins R Peto R Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side effects from 33 randomized controlled trials Eur Heart J 6 1985 556 585
72. Gruppo Italiano per lo studio della Streptochinase Nell'infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1:397-402
73. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-60
74. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-2: a factorial randomized trial of alteplase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336:65-71
75. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990; 336:71-5
76. ISIS-3 Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753–70
77. Topol EJ George BS Kereiakes DJ A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction Circulation 79 1989 281 286
78. Bleich SD Nichols TC Schumacher RR Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction Am J Cardiol 66 1990 1412 1417
79. Hsia J Hamilton WP Kleiman N A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue-type plasminogen activator for acute myocardial infarction N Engl J Med 323 1990 1433 1437
80. De Bono DP Simoons LL Tijssen J ECSG: the effect of early intravenous heparin on coronary patency, infarct size and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial Br Heart J 67 1992 122 128
81. Thompson PL Aylward PE Federma J A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction Circulation 83 1991 1534 1542
82. Meijer A Verheugt FWA Werter CJPJ Aspirin versus Coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study: results of the APRICOT study Circulation 87 1993 1524 1530
83. Prins MH Hirsh J. Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction Am J Cardiol 67 1991 3A 11A
84. Hull RD Raskob GE Hirsh J Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis N Engl J Med 315 1986 1109 1114
85. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673-82
86. Veterans Administration Cooperative Group. Long-term anticoagulant therapy after myocardial infarction: a study of 747 patients in 15 hospitals. JAMA 1965; 193:929-34
87. Ebert RV Borden CV Hipp HR Long-term anticoagulant therapy after myocardial infarction: final report of the Veterans Administration Cooperative Study JAMA 207 1969 2263 2267
88. Second Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council. An assessment of long-term anticoagulant administration after cardiac infarction. BMJ 1964; 2:837-43
89. Breddin D Loew D Lechner K The German-Austrian Aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction Circulation 62 suppl 5 1980 V63 72
90. International Anticoagulant Review Group. Collaborative analysis of long-term anticoagulant administration after acute myocardial infarction. Lancet 1970; 1:203-09
91. Report of the 60+ Reinfarction Study Research Group. A double-blind trial to assess long-term anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980; 2: 989–94
92. Sixty Plus Reinfarction Study Research Group. Risks of longterm and anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1982; 1:64-8
93. Smith P Arnesen H Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction N Engl J Med 323 1990 147 152
94. ASPECT Research Group. Effect of long-term oral anticaogulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343:499-503
95. The EPSIM Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982; 307:701-08
96. Neri Serneri GG Rovelli F Gensini GF Effectiveness of low-dose heparin in prevention of myocardial reinfarction Lancet 1 1987 937 942
97. Collins R Scrimgeour A Yusuf S Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin N Engl J Med 318 1988 1162 1173
98. Cairns JA Singer J Gent M One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina, or other chest pain in Hamilton, Ontario, a city of 375,000 people Can J Cardiol 5 1989 239 246
99. Simoons ML Vos J Tijssen JGP Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year followup of a trial conducted by the Interuniversity Cardiology Institute of the Netherlands J Am Coll Cardiol 14 1989 1609 1615
100. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449-57
101. Cairns JA Markham BA. Economics and efficacy in choosing oral anticoagulants or aspirin after myocardial infarction JAMA 273 1995 965 967
102. Stein B Fuster V. Clinical pharmacology of platelet inhibitors Fuster V Verstraete M Thrombosis in cardiovascular disorders 1992 WB Saunders Philadelphia 99 119
103. Fornaro G Rossi P Mantica PG Indobufen in the prevention of thromboembolic complications in patients with heart disease: a randomized, placebo-controlled, double-blind study Circulation 87 1993 162 164
104. Friedman PL Brugada P Kuck K Coronary vasoconstrictor effect of indomethacin in patients with coronary artery disease N Engl J Med 305 1981 1171 1175
105. Elwood PC Williams WO. A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction J R Coll Gen Pract 29 1979 413 416
106. Elwood PC. Early use of aspirin [letter to the editor] Lancet 1 1990 486
107. ISIS (International Studies of Infarct Survival) Pilot Study Investigators. Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. Eur Heart J 1987; 8:634-42
108. Coller BS. Platelets and thrombolytic therapy N Engl J Med 322 1990 32 42
109. Verheught FWA Kupper AJF Galema TW Low dose aspirin after early thrombolysis in anterior wall acute myocardial infarction Am J Cardiol 61 1988 904 906
110. Yusuf S Sleight P Held P Routine medical management of acute myocardial infarction: lessons from overviews of recent randomized controlled trials Circulation 82 suppl 2 1990 II-117-34
111. Elwood PC Cochrane AL Burr ML A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction BMJ 1 1974 436 440
112. The Coronary Drug Project Research Group. Aspirin in coronary heart disease. J Chronic Dis 1976; 29:625-42
113. Breddin K Loew D Lechner K Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon Hemostasis 9 1980 325 344
114. Elwood PC Sweetnam PM. Aspirin and secondary mortality after myocardial infarction Lancet 2 1979 1313 1315
115. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980; 243:661-69
116. The Persantine-Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation 1980; 62:449-61
117. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: 1. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106
118. UK-TIA Study Group. United Kingdom transient ischemic attack (UK-TIA) Aspirin Trial: interim results. BMJ 1988; 296: 316–30
119. 2 but not of systemic prostacycline by controlled-release aspirin N Engl J Med 325 1991 1137 1141
120. The Anturane Reinfarction Trial Research Group. Sulfinpyrazone in the prevention of cardiac death after myocardial infarction: the Anturane Reinfarction Trial. N Engl J Med 1978; 298:289-300
121. The Anturane Reinfarction Trial Research Group. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 1980; 302:250-56
122. Temple R Pledger GW. The FDAs critique of the Anturane Reinfarction Trial N Engl J Med 303 1980 1488 1492
123. Anturane Reinfarction Trial Policy Committee. The Anturane Reinfarction Trial: re-evaluation of outcome. N Engl J Med 1982; 306:1005-08
124. Report from the Anturane Reinfarction Italian Study. Sulfinpyrazone in post-myocardial infarction. Lancet 1982; 1:237-48
125. Klimt CR Knatterud GL Stamler J Persantine-Aspirin Reinfarction Study: II. Secondary coronary prevention with persantine and aspirin J Am Coll Cardiol 7 1986 251 269
126. Gent M Blakely JA Easton JD The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke Lancet 1 1989 1215 1220
127. Hass WK Easton JD Adams HP A randomized trial comparing ticlopidine hydrochloride with aspirin for the presentation of stroke in high-risk patients N Engl J Med 321 1989 501 507
128. Janzon L Bergqvist D Boberg J Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine: results from STIMS, the Swedish Ticlopidine Multicentre Study J Intern Med 227 1990 301 308
129. Lewis HD Davis JW Archibald DG Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study N Engl J Med 309 1983 396 403
130. Cairns JA Gent M Singer J Aspirin, sulfinpyrazone, or both, in unstable angina: results of a Canadian multicenter clinical trial N Engl J Med 313 1985 1369 1375
131. Balsano F Rizzon P Violi F Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter trial Circulation 82 1990 17 26
132. Nichol ES Phillips WC Casten GG. Virtue of prompt anticoagulant therapy in impending myocardial infarction: experiences with 318 patients during a 10-year period Am Intern Med 50 1959 1158 1173
133. Beamish RE Storrie VM. Impending myocardial infarction: recognition and management Circulation 21 1960 1107 1115
134. Wood P. Acute and subacute coronary insufficiency BMJ 1 1961 1779 1782
135. Vakil RJ. Preinfarction syndrome-management and follow-up Am J Cardiol 14 1964 55 63
136. Telford AM Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome Lancet 1 1981 1225 1228
137. Williams DO Kirby MG McPherson K Anticoagulant treatment in unstable angina Br J Clin Pract 40 1986 114 116
138. Théroux P Ouimet H McCans J Aspirin, heparin, or both to treat acute unstable angina N Engl J Med 319 1988 1105 1111
139. Théroux P Waters D Qui S Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina Circulation 88 pt I 1993 2045 2048
140. The RISC Group. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–30, 139.
141. Théroux P Waters D Lam J Reactivation of unstable angina following discontinuation of heparin N Engl J Med 327 1992 141 145
142. Cohen M Adams PC Parry G Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonoption aspirin users: primary end point analysis from the ATACS trial Circulation 89 1994 81 88
143. Holdright D Patel D Cunningham D Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina J Am Coll Cardiol 24 1994 39 45
144. Neri Serneri GG Gensini GF Poggesi L Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina Lancet 335 1990 615 618
145. Théroux P White H David D A heparin-controlled study of MK-383 in unstable angina [abstract] Circulation 90 1994 1 231 90:1-231
146. Théroux P Kouz S Knudtson M A randomized double-blind controlled trial with the non-peptidic platelet GPIIb/IIIa antagonist RO 44–9883 in unstable angina [abstract] Circulation 90 1994 1 231
147. Simoons M Jan de Boer M van den Brand MJBM Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina Circulation 89 1994 596 603
148. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330:956-61
149. The Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129–35
150. Peto R Gray R Collins R Randomized trial of prophylactic daily aspirin in British male doctors BMJ 296 1988 313 316
151. Hennekens CH Buring JE Sandercock P Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease Circulation 80 1989 749 756
152. Manson JE Stampfer J Colditz GA A prospective study of aspirin use and primary prevention in cardiovascular disease in women JAMA 266 1991 521 527
153. Buring JE Hennekens CH The women's health study: summary of the study design J Myocardial Ischemia 4 1992 27 29 for Women's Health Study Research Group.
154. Ridker PM Manson JAE Gaziano JM Low-dose aspirin therapy for chronic stable angina: a randomized, placebo-controlled clinical trial Ann Intern Med 114 1991 835 839
155. Juul-Moller S Edvardsson N Jahnmatz B Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris Lancet 340 1992 1421 1425
156. Komrad MS Coffey CE Coffey KS Myocardial infarction and stroke Neurology 34 1984 1403 1409
157. Turpie AGG Gent M Laupacis A Comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement N Engl J Med 329 1993 524 529